Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting
Open accessThe DOI matches its Crossref record.
Abstract
The aim of the present study was to prepare a novel CD133 aptamer modified DTX liposome system and investigate its characteristics in vitro and in vivo studies. In this study, the CD133-DTX LP was prepared by the thin-film hydration method and with the particle size of 100-120 nm. The TEM photomicrographs were smooth, sub-spherical in shape and aggregated to form small clusters. In vitro, a relatively slower DTX release profile was observed in CD133-DTX LP due to the presence of CD133 aptamers on the outer surface which might hinder the drug release. The drug release mechanism fit well with the Higuchi equation better. In cytotoxicity study, CD133 aptamers modified DTX LP significantly decreased cell proliferation and improved the therapeutic efficiency. In vivo imaging result indicated that CD133-DTX LP had very good tumour targeting ability. In vivo antitumour activity indicated that the CD133-DTX LP showed a significant antitumour activity in A549 tumour mice, with a very low systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Fu, Z., & Xiang, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239123 · Cited by 231
Priya, S., Desai, V. M., & Singhvi, G. (2023) · ACS Omega · doi:10.1021/acsomega.2c05976 · Cited by 228
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140
Lung cancer stem cell markers as therapeutic targets: An update on signaling pathways and therapies
Zheng, Y., Wang, L., Yin, L., Yao, Z., Tong, R., Xue, J., & Lu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873994 · Cited by 97
Self-citation
Metadata
- Authors
- Ma, J., Zhuang, H., Zhuang, Z., Lu, Y., Xia, R., Gan, L., & Wu, Y.
- Venue
- Artificial Cells, Nanomedicine, and Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2017-10-30
- Volume
- 46
- Issue
- 8
- Pages
- 1-8
- ISSN
- 2169-1401 (ISSN-L)
- 2169-141X
- OpenAlex
- W2767019153
- Cited by
- 45
- References
- 0
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. https://app.cochat.ai/papers/10.1080/21691401.2017.1394874
- The paper
- Ma, J., Zhuang, H., Zhuang, Z., Lu, Y., Xia, R., Gan, L., & Wu, Y. (2017). Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. Artificial Cells, Nanomedicine, and Biotechnology. https://doi.org/10.1080/21691401.2017.1394874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.